Juan Carlos Bello-Muñoz

Juan Carlos Bello-Muñoz

Auto-generated profile, based on publicly available information

Juan Carlos Bello-Muñoz

Department of Maternal-Fetal Medicine, National Institute of Perinatology (INper)

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in The Lancet
Verified
Journal Article
Closed access
MGMaria Goya
Maria Goya
LPLaia Pratcorona
Laia Pratcorona
CMCarme Merced
Carme Merced
CRCarlota Rodó
Carlota Rodó
LVLeonor Valle
Leonor Valle
ECElena Carreras
Elena Carreras

14 June 2010 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
PDF file
MSMaría Ángeles Sánchez-Durán
María Ángeles Sánchez-Durán
JBJuan Carlos Bello-Munoz
Juan Carlos Bello-Munoz
ICIsaac Cebrecos
Isaac Cebrecos
TSTeresa Higueras Sanz
Teresa Higueras Sanz
JMJuan Sagalá Martinez
Juan Sagalá Martinez
LRLluis Cabero Roura
Lluis Cabero Roura
Objective. To describe the prevalence of congenital varicella syndrome (CVS) within the population of presumably infected pregnant women. Methods. From 1993 to 2006, all women who presented vesicular rash or a suspicious contact were referred and evaluated in a special unit at our center. Those with residual immunity or were serologically negative were precluded from this study. Positive IgM cases underwent monthly ultrasound scans (US), fetal blood (FB) sampling (including IgM anti VZV and virus culture). Amniotic fluid sample for PCR was added to the diagnosis of positive IgM cases after 1997. Results. A total of 276, of the 566 consulted women, tested positive for IgM anti VZV. Seventeen (6%) were excluded because of an unadvised termination of pregnancy and seven (2.55%) miscarried. Only seven (2.7%) were considered highly likely to have a VZV fetal infection. One case showed positive IgM in FB but developed normally. Another fetus showed positive PCR and infection was confirmed post TOP. Four cases that underwent TOP and histochemistry confirmed no more cases. Complete post-natal follow-up was carried out. The asymptomatic infected child grew healthy until the completion of screening tests when it reached 5 years old. Conclusion. The fetal infection rate in this cohort was 0.8%, but the best expected prevalence of CVS, according to our findings, should be 0.39% among infected women. This data should be considered and used during parental counselling.

11 October 2012 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
ECElena Carreras
Elena Carreras
SASilvia Arévalo
Silvia Arévalo
JBJuan Carlos Bello‐Muñoz
Juan Carlos Bello‐Muñoz
MGMaria Goya
Maria Goya
CRCarlota Rodó
Carlota Rodó
LCLluís Cabero
Lluís Cabero

22 April 2013 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
NLNatalia Lenis-Cordoba
Natalia Lenis-Cordoba
MSMaría Ángeles Sánchez-Durán
María Ángeles Sánchez-Durán
JBJuan Carlos Bello-Muñoz
Juan Carlos Bello-Muñoz
JSJuan Sagalá-Martinez
Juan Sagalá-Martinez
NCNazareth Campos
Nazareth Campos
LCLluis Cabero-Roura
Lluis Cabero-Roura
Aim: To compare the rate of pregnancy loss between twin pregnancies undergoing a genetic amniocentesis (AC) and a control group with similar characteristics. Methods: Prospective observational study on a population of twin pregnancies referred to our prenatal diagnosis unit for screening from 1990 to 2010. Those women referred for an AC were compared with those without indication for the procedure. Primary outcomes were pregnancy loss within the 4 weeks after procedure and pregnancy loss before 24 weeks. Secondary outcome included neonatal morbidity, gestational age at delivery and birth weight. Results: Maternal characteristics were similar for both groups, except for maternal age. There was neither difference in the pregnancy loss rate within 4 weeks (2.7 versus 2.6%) nor in the loss rate before 24 weeks of gestation (1.2 versus 1.1%). Gestational age at birth was 36 weeks for both groups. Chorionicity and gestational age at procedure played no role in modifying the risk. Conclusion: Based on our results, there is no difference in the pregnancy loss rate in twin gestations, regardless of chorionicity or gestational age at procedure, either within 4 weeks after the procedure or before 24 weeks, in patients who undergo AC when compared with patients who do not.

20 June 2014 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
PDF file
EOEsteban Mauricio Orozco
Esteban Mauricio Orozco
MSMaría Ángeles Sánchez-Durán
María Ángeles Sánchez-Durán
JBJuan Carlos Bello-Muñoz
Juan Carlos Bello-Muñoz
JSJuan Sagalá
Juan Sagalá
ECElena Carreras
Elena Carreras
LRLluis Cabero Roura
Lluis Cabero Roura
Objective: To evaluate the diagnostic accuracy of different beta-human chorionic gonadotrophin (ß-hCG) levels measurement, for predicting success of medical treatment in cases diagnosed as tubal ectopic pregnancy (TEP). Design: Five-year prospective observational study. Setting: Prenatal Diagnosis Unit, Vall d'Hebron University Hospital – Barcelona. Patients: TEP cases fulfilling criteria for medical treatment with Methotrexate. Interventions: ß-hCG levels were measured on d 0, 4 and 7 of treatment. Results were compared by non-parametrical tests. A ROC curve was plotted to define cut-off points. Diagnostic accuracy of the different measurements was evaluated. Main outcome measure: Failure of treatment defined as need for surgical treatment or persistence of high ß-HCG levels despite treatment. Results: 126 women were diagnosed as TEP, eligible for medical treatment. There were no differences in parity, age, previous TEP, or adnexal mass size. Success rate was 88%. ß-HCG decreased significantly more, between days 0–7 and 4–7, in the successful cases. LR for success prediction was 6.2 and 7.8 for ß-HCG levels at days 4 and 7 respectively, 4.02 and 2.47 for decrement between days 0–7 (25%) and 4–7 (20%), respectively. Conclusion: ß-hCG cutoff values have a potential for predicting a successful medical treatment of TEP.

23 March 2015 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
VAVania Aldrete-Cortez
Vania Aldrete-Cortez
LSLourdes Schnaas
Lourdes Schnaas
APAdrián Poblano
Adrián Poblano
PCPaul Carrillo‐Mora
Paul Carrillo‐Mora
EOEfraín Olivas‐Peña
Efraín Olivas‐Peña
AMArmando Mansilla‐Olivares
Armando Mansilla‐Olivares